- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01003912
Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases (IUHST-001)
Treatment of Early Infantile-Onset Lysosomal Storage Diseases With Fetal Umbilical Cord Blood (UCB) Transplantation
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the safety of first trimester fetal stem cell therapy using unrelated donor partially HLA-matched stem and progenitor cells derived from human umbilical cord blood for the treatment of selected lysosomal storage diseases that are known to cause severe and irreversible neurological disability in early infancy and which are lethal in childhood.
This study is designed as a prospective phase I open-label single center trial. It is designed to asses the safety and feasibility of administration of ALD-601 UCB cells to first trimester fetuses known to be affected with a lethal lysosomal storage disease. The sample size is 12 patients enrolled in cohorts of size 3. Safety measures will be monitored by an independent DSMC in each of the 4 cohorts prior to proceeding to the next cohort.
Biological parents being considered for therapy will have HLA testing, mutation analysis for disease status, and psychological counseling. Mothers will have ultrasounds for gestational age and chorion villus testing for mutation analysis for Krabbe, MLD, Tay Sachs, Sandhoff, or PMD (whichever appropriate). A crown-rump length will be determined the day before the scheduled transfer. The fetal weight will be calculated from formula: Y (kg) = (2.9026 x 10-1) (X 2.6528). The estimated fetal weight at that gestational age would be about 0.5 ounces or 14 grams. A suitably matched unrelated umbilical cord blood will be identified and the 20% portion will be manipulated for the isolation of ALD-601 cells. ALD-601 (ALDHbr) cells are isolated by high speed flow sorting on the FACSAria (BD Biosciences). Upon completion of the sort, ALD-601 UCB cells are counted, viability is determined, and the cellular composition of the sample is measured by analytical flow cytometry using fluorescence antibodies to lineage marker for T-cells, granulocytes, monocytes, and erythrocytes. The content of ALDHbr cells is also confirmed by analytical flow cytometry. A dose of 1 x 105 - 2 x 106 cells/kg of estimated fetal weight is suspended in 300 microliters of Cellgenix Stem Cell Medium (CellGenix, Inc.). Release criteria will allow a maximum of 5 x 104 T cells/kg. If the sorted sample contains greater than 5 x 104 T cells/kg it is re-sorted using the FACSAria and re-evaluated for cell number, viability, and cellular content. Sterility testing will include Bac-T/ALERT cultures, endotoxin measurement (LAL), and gram stain. After meeting criteria for product release, ALD-601 is transported at 2-8 degree C in a validated cooler to Duke and released to the Stem Cell Laboratory. Duke personnel will transport the cooler containing the ALD-601 product to the ultrasound suite, where the medical team will allow the ALD-601 to warm briefly to room temperature prior to injection. Under continuous ultrasound guidance, a 22-gauge X 5 inch procedure needle will be used to puncture the fetal peritoneal cavity. 100 microliters of sterile saline will be instilled to confirm intraperitoneal placement. The stem cell infusion will then be injected through the needle followed by the injection of 200 microliters (dead space of the needle: 60 microliters) to displace all cells from the dead space of the needle. An ultrasound will be performed 24 hours later to confirm fetal viability. A subsequent ultrasound will be undertaken at 18 weeks gestation to confirm viability, assess detailed fetal anatomy and adequate serial fetal growth.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center Pediatric Blood and Marrow Transplant
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fetus with known enzymatic and, if possible, mutation diagnosis of selected lysosomal storage diseases, and history of enzymatic or mutation diagnosis of a previously affected family member.
- Krabbe disease
- Infantile metachromatic leukodystrophy disease (MLD)
- Tay Sachs or Sandhoff (GM2 gangliosidoses) disease
- Pelizaeus-Merzbacher disease (PMD).
- Both parents have the "at risk" genotype
- Both parents agree to psychological counseling prior to CVS
- Both parents agree to delivery of subject at Duke University
- Gestational age of < 9 weeks by sure menstrual dating or ultrasound of a natural pregnancy.
- Singleton fetus
- No evidence of abnormal nuchal thickening on preliminary ultrasound prior to chorion villus biopsy
Exclusion Criteria:
- Pregnancy by in vitro fertilization
- Evidence of a nuchal translucency of > 3.0 mm at the time of the ultrasound for the chorion villus biopsy.
- HIV, hepatitis C or hepatitis B positive maternal status
- Active infection in the mother at the time of scheduled CVS or cell injection as determined by clinical practice
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine whether immune tolerance and donor cell engraftment can be achieved through first trimester injection of donor cells to fetus's diagnosed with lethal LSDs.
Time Frame: after 3 patients
|
after 3 patients
|
Safety and feasibility of fetal intrap.
Time Frame: after 3 patients
|
after 3 patients
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Donor chimerism for neonate at birth and 7 days post delivery.
Time Frame: after 3 patients
|
after 3 patients
|
Establishment of threshold enzyme levels in neonate at birth and 7 days post delivery.
Time Frame: after 3 patients
|
after 3 patients
|
Donor chimerism for mother post delivery and 1 year post date of birth.
Time Frame: after 3 patients
|
after 3 patients
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00010188
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lysosomal Storage Diseases
-
National Institute of Neurological Disorders and...CompletedLysosomal Storage DiseaseUnited States, France, Israel, Netherlands
-
University of FloridaAmicus TherapeuticsCompletedLysosomal Storage Diseases | Glycogen Storage Disease Type II | Pompe DiseaseUnited States
-
Eunice Kennedy Shriver National Institute of Child...RecruitingLysosomal Storage Disease | Cholesterol MetabolismUnited States
-
University of LausanneUniversity of Modena and Reggio EmiliaCompletedN-Acetylneuraminic Acid Storage DiseaseSwitzerland, Italy
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
-
Genzyme, a Sanofi CompanyActive, not recruitingGlycogen Storage Disease Type IIFrance
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIChina
-
Duke UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedGlycogen Storage Disease Type IIUnited States
-
Columbia UniversityWithdrawnGlycogen Storage Disease Type IIUnited States
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
Clinical Trials on ALD-601
-
AldagenTerminatedMucopolysaccharidosis | Inborn Errors of Metabolism | Lysosomal Storage Disorders | Inherited Metabolic Diseases | Peroxisomal Storage DiseasesUnited States
-
National Taiwan University HospitalCompleted
-
Leipzig University Medical CenterEuropean Leukodystrophy AssociationCompletedX-linked AdrenoleukodystrophyGermany
-
ADC Therapeutics S.A.TerminatedAdvanced Solid TumorsUnited States
-
C.B. Fleet Company, Inc.CompletedBowel Cleansing Prior to ColonoscopyUnited States
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
-
Motric BioRecruitingStroke | Multiple Sclerosis | Cerebral Palsy | Spinal Cord Injuries | Dystonia | Muscle Spasticity | Hereditary Spastic Paraplegia | Hypertonia, MuscleUnited States
-
Henry FriedmanCompletedGrade IV Malignant GliomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
TransMolecularUnknownAstrocytoma | Glioblastoma Multiforme | Malignant Glioma | GBM | OligodendrogliomaUnited States